Real world experience and clinical aspects of MPN treatments
H. Gisslinger, R. Kušec
European PV guidelines by comparison. Where are we going?
R. Kušec
MIND – MPN database of the Czech Leukemia Study Group
M. Doubek
Polish experience with ropeginterferon alfa-2b in patients suffering from polycythemia vera
T. Sacha
A potentially new thromboembolic event scoring system in polycythemia vera patients: an audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register
M. Egyed
Essential thrombocythemia: what comes after hydroxyurea, pegylated interferon and anagrelide?
A. Rüfer
When to use ropeginterferon alfa-2b in patients with polycythemia vera? Real world evidence from the Clinical Institute from Bucharest, Romania
I. Ursuleac
Aiming for disease modification in PV – my personal experience
D. Lechner-Radner
Discussion
Open discussion at speakers‘ corner